Share This Page
Drugs in ATC Class C05BB
✉ Email this page to a colleague
Drugs in ATC Class: C05BB - Sclerosing agents for local injection
| Tradename | Generic Name |
|---|---|
| ASCLERA | polidocanol |
| SODIUM TETRADECYL SULFATE | sodium tetradecyl sulfate |
| SOTRADECOL | sodium tetradecyl sulfate |
| TRAVERT 10% IN PLASTIC CONTAINER | invert sugar |
| VARITHENA | polidocanol |
| >Tradename | >Generic Name |
Showing 1 to 5 of 5 entries
C05BB Market Analysis and Financial Projection
The global sclerotherapy market, particularly for agents classified under ATC code C05BB (Sclerosing agents for local injection), demonstrates robust growth driven by rising venous disease prevalence and advancements in minimally invasive treatments. Here's a detailed analysis of market dynamics and patent trends:
Market Dynamics
Growth Trajectory
- The sclerotherapy market was valued at $1.15 billion in 2024 and is projected to grow at 4.4% CAGR through 2030[1]. Alternative estimates suggest growth from $1.02 billion in 2024 to $1.60 billion by 2031 (6.7% CAGR)[17].
- Key drivers include aging populations, increasing varicose vein cases, and demand for non-surgical treatments.
Segmentation
- By Agent:
- Detergents (e.g., sodium tetradecyl sulfate, polidocanol) dominated with 43.5% market share in 2024 due to efficacy and safety[1][6].
- Osmotic agents (e.g., hypertonic saline) and chemical irritants (e.g., chromated glycerin) hold smaller shares.
- By Type:
- Liquid sclerotherapy remains standard, but foam sclerotherapy is gaining traction for better vein occlusion rates[8][17].
Geographical Insights
- North America leads with 44.5% market share[1], driven by advanced healthcare infrastructure and high procedural adoption.
- Europe follows, supported by favorable reimbursement policies and an aging population.
- Asia-Pacific is the fastest-growing region due to improving healthcare access and rising disposable incomes[16][17].
Patent Landscape
Key Innovations
- Formulation Patents:
- WO2004089358A1 (2004): Combines sodium tetradecyl sulfate (STS) and polidocanol with glycerin or hydroxyethyl starch for enhanced sclerosing effects[5].
- USRE40640E1 (1993): Covers injectable microfoam formulations using STS/polidocanol for prolonged vein contact[10].
- Therapeutic Expansion:
- US20090202467A1 (2009): Combines sclerosing agents with vasoconstrictors (e.g., oxymetazoline) to improve efficacy[11].
- Patent No. 102018000006109 (2020): Explores diluted polidocanol for immunomodulation and anti-inflammatory applications beyond varicose veins[13].
Competitive Strategies
- Major players like Merz Pharma, BTG, and LGM Pharma focus on mergers, acquisitions, and novel formulations[1][6].
- Regulatory Milestones: FDA approval of STS (2004) and polidocanol microfoam (post-2008 trials) validated safety and efficacy[8][10].
ATC Classification & Industry Impact
- C05BB codifies sclerosing agents, streamlining drug tracking and market analysis. For example, Norway’s prescription database uses ATC codes to monitor consumption trends[12].
- DDD (Defined Daily Dose): While DDDs aren’t established for C05BB, the ATC framework aids in regional and therapeutic comparisons[9][12].
Challenges & Opportunities
- Cost Barriers: High diagnostic imaging expenses may limit access in developing regions[16].
- Innovation Gaps: Opportunities exist in expanding applications (e.g., cancer therapy, immunomodulation) and improving foam stability[13][18].
Key Takeaways
- Market Growth: Sustained by minimally invasive demand and aging demographics.
- Innovation Focus: Patents highlight formulation enhancements and therapeutic diversification.
- Regional Leadership: North America and Europe dominate, but Asia-Pacific offers untapped potential.
"The sclerotherapy market is poised for growth, with detergents like STS and polidocanol remaining cornerstones of innovation." — Grand View Research[1]
References
- https://www.grandviewresearch.com/industry-analysis/sclerotherapy-market
- https://www.drugpatentwatch.com/p/atc-class/C05B
- https://www.ded.uscourts.gov/sites/ded/files/opinions/14-1171_0.pdf
- https://www.fortunebusinessinsights.com/industry-reports/multiple-sclerosis-drugs-market-100386
- https://patents.google.com/patent/WO2004089358A1/en
- https://www.prnewswire.com/news-releases/global-sclerotherapy-market-by-agent-by-type-by-region-industry-analysis-and-forecast-2020---2026-301168560.html
- https://bioportal.bioontology.org/ontologies/ATC
- https://pmc.ncbi.nlm.nih.gov/articles/PMC2787977/
- https://atcddd.fhi.no/atc_ddd_index/?code=C05BB05
- https://patents.google.com/patent/USRE40640E1/en
- https://patents.google.com/patent/US20090202467A1/en
- https://fhi.brage.unit.no/fhi-xmlui/bitstream/handle/11250/2980341/Berg-2019-Res.pdf?sequence=1
- https://www.ippocrateparma.it/en/who-we-are/patent/
- https://go.drugbank.com/drugs/DB00464
- https://pubchem.ncbi.nlm.nih.gov/compound/Phenole
- https://straitsresearch.com/report/lymphedema-diagnostics-market
- https://www.reanin.com/reports/global-sclerotherapy-market
- https://www.businesswire.com/news/home/20250110674650/en/Medical-PET-Patent-Landscape-Report-2025-Covering-1408-Patents-Filed-from-2010-to-2024---ResearchAndMarkets.com
More… ↓
